VALNEVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Valneva SE on Behalf of Valneva Stockholders and Encourages Investors to Contact the Firm

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Valneva SE regarding possible violations of federal securities laws and unlawful business practices following adverse events related to its chikungunya virus vaccine, IXCHIQ [2][3][4] Group 1: Legal Investigation - The law firm is encouraging Valneva stockholders who have suffered losses to contact them for discussions about their legal rights [1][5] - The investigation is focused on whether Valneva has engaged in unlawful business practices that may have affected stockholder interests [2] Group 2: Recent Events Impacting Valneva - On February 25, 2025, the CDC announced an investigation into five hospitalizations for cardiac or neurologic events following vaccination with IXCHIQ, leading to a 13.57% drop in Valneva's ADR price, closing at $6.75 on February 28, 2025 [3] - On August 22, 2025, the FDA suspended the marketing application for IXCHIQ due to safety concerns, resulting in an 18.99% decline in Valneva's ADR price, closing at $9.43 on August 25, 2025 [4]